Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;34(7):e70132.
doi: 10.1111/exd.70132.

Ruxolitinib Alleviates Inflammation and Fortifies Skin Barrier Function Through Dampening IL-13

Li Fang Koh  1 , Muhammad Jasrie Firdaus  1 , Yohei Natsuaki  1 , Sho Hanakawa  1   2 , Khek-Chian Tham  1   3 , Declan P Lunny  1   3 , Belle L H Yap  1 , Satoshi Nakamizo  2 , Eori Nam  4 , Ji Eun Lee  4 , Ying Xiu Toh  3 , Nelson M H Teo  5 , Thiam Chye Lim  5 , E Birgitte Lane  1   3 , Kenji Kabashima  1   2   3   6 , Baptiste Janela  1   3   7   8   9 , John E Common  1   3   10
Affiliations

Ruxolitinib Alleviates Inflammation and Fortifies Skin Barrier Function Through Dampening IL-13

Li Fang Koh et al. Exp Dermatol. 2025 Jul.

Abstract

Atopic dermatitis (AD) is a prevalent inflammatory skin disorder characterized by an impaired skin barrier, dysregulated immune system and pruritis. Emerging pharmaceutical therapies for AD include selective Janus kinase (JAK) inhibitors such as ruxolitinib, the first dual JAK1/JAK2 inhibitor approved by the US Food and Drug Administration. This study aimed to evaluate the effects of ruxolitinib on AD-related symptoms using mouse and human skin models. AD-related symptoms were assessed in MC903/ruxolitinib-treated mice, including ear swelling, histological analysis, pruritus, serum biomarker quantification and immune cell analysis. Additionally, immunohistochemistry and transcriptome analysis were conducted on AD-related cytokine-treated reconstructed human skin (RHS) and ruxolitinib-treated human skin explants with and without tape-stripping. Ruxolitinib-treated mice exhibited reduced inflammation, including decreased ear swelling and diminished pruritus. Furthermore, reductions in immune cell populations, including T cells and serum biomarker IL-13, were observed in ruxolitinib-treated mice. Transcriptome analysis revealed increased STAT3 expression and decreased skin barrier gene FLG in AD-related cytokine-treated RHS. Regardless of tape stripping, ruxolitinib-treated skin explants exhibited decreased IL13RA1 expression and increased expression of skin barrier genes FLG, FLG2 and LOR. Ruxolitinib treatment in mice resulted in decreased inflammation and pruritus, along with increased expression of skin barrier proteins through downregulation of IL-13. Consistently, ruxolitinib-treated human skin explants demonstrated enhanced expression of skin barrier proteins, while IL-13 treatment of RHS led to downregulation of these proteins. These findings support data from human clinical trials indicating reduced SCORAD, pruritus and inflammatory phenotypes in AD patients treated with ruxolitinib.

Keywords: JAK/STAT; MC903; atopic dermatitis; reconstructed human skin; ruxolitinib; skin explants.

PubMed Disclaimer

References

    1. S. M. Langan, A. D. Irvine, and S. Weidinger, “Atopic Dermatitis,” Lancet 396, no. 10247 (2020): 345–360.
    1. K. Kabashima, “New Concept of the Pathogenesis of Atopic Dermatitis: Interplay Among the Barrier, Allergy, and Pruritus as a Trinity,” Journal of Dermatological Science 70, no. 1 (2013): 3–11.
    1. L. Paternoster, M. Standl, J. Waage, et al., “Multi‐Ancestry Genome‐Wide Association Study of 21,000 Cases and 95,000 Controls Identifies New Risk Loci for Atopic Dermatitis,” Nature Genetics 47, no. 12 (2015): 1449–1456.
    1. S. Weidinger, L. A. Beck, T. Bieber, K. Kabashima, and A. D. Irvine, “Atopic Dermatitis,” Nature Reviews Disease Primers 4, no. 1 (2018): 1.
    1. D. M. Schwartz, M. Bonelli, M. Gadina, and J. J. O'Shea, “Type I/II Cytokines, JAKs, and New Strategies for Treating Autoimmune Diseases,” Nature Reviews Rheumatology 12, no. 1 (2016): 25–36.

MeSH terms

LinkOut - more resources